MEI Pharma (MEIP) Competitors $2.33 +0.03 (+1.35%) Closing price 03/14/2025 03:55 PM EasternExtended Trading$2.33 0.00 (-0.04%) As of 03/14/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MEIP vs. KPTI, BYSI, ENTX, CTOR, PYXS, QNCX, PMVP, MRSN, VHAQ, and VORShould you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Karyopharm Therapeutics (KPTI), BeyondSpring (BYSI), Entera Bio (ENTX), Citius Oncology (CTOR), Pyxis Oncology (PYXS), Quince Therapeutics (QNCX), PMV Pharmaceuticals (PMVP), Mersana Therapeutics (MRSN), Viveon Health Acquisition (VHAQ), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. MEI Pharma vs. Karyopharm Therapeutics BeyondSpring Entera Bio Citius Oncology Pyxis Oncology Quince Therapeutics PMV Pharmaceuticals Mersana Therapeutics Viveon Health Acquisition Vor Biopharma MEI Pharma (NASDAQ:MEIP) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment. Do analysts recommend MEIP or KPTI? MEI Pharma presently has a consensus target price of $7.00, suggesting a potential upside of 200.30%. Karyopharm Therapeutics has a consensus target price of $57.50, suggesting a potential upside of 751.85%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MEI Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, MEIP or KPTI? MEI Pharma has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Does the media prefer MEIP or KPTI? In the previous week, MEI Pharma and MEI Pharma both had 3 articles in the media. Karyopharm Therapeutics' average media sentiment score of 1.33 beat MEI Pharma's score of 0.30 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MEI Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, MEIP or KPTI? MEI Pharma has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMEI Pharma$65.30M0.24$17.78M-$5.73-0.41Karyopharm Therapeutics$145.24M0.39-$143.10M-$15.29-0.44 Do insiders and institutionals have more ownership in MEIP or KPTI? 52.4% of MEI Pharma shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 3.1% of MEI Pharma shares are owned by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is MEIP or KPTI more profitable? MEI Pharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets MEI PharmaN/A -84.92% -67.53% Karyopharm Therapeutics -52.62%N/A -39.58% Does the MarketBeat Community favor MEIP or KPTI? Karyopharm Therapeutics received 126 more outperform votes than MEI Pharma when rated by MarketBeat users. Likewise, 72.42% of users gave Karyopharm Therapeutics an outperform vote while only 62.88% of users gave MEI Pharma an outperform vote. CompanyUnderperformOutperformMEI PharmaOutperform Votes41562.88% Underperform Votes24537.12% Karyopharm TherapeuticsOutperform Votes54172.42% Underperform Votes20627.58% SummaryKaryopharm Therapeutics beats MEI Pharma on 11 of the 17 factors compared between the two stocks. Remove Ads Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEIP vs. The Competition Export to ExcelMetricMEI PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.53M$7.02B$5.67B$8.12BDividend YieldN/A2.76%4.40%4.10%P/E Ratio-0.416.2923.9019.07Price / Sales0.24232.75395.6188.24Price / Cash0.4465.6738.1134.64Price / Book0.706.596.834.29Net Income$17.78M$142.18M$3.20B$247.56M7 Day Performance-4.47%1.18%8.77%2.11%1 Month Performance-13.35%-8.94%-0.35%-9.37%1 Year Performance-39.14%-5.83%13.04%4.01% MEI Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEIPMEI Pharma3.8627 of 5 stars$2.33+1.3%$7.00+200.3%-39.1%$15.53M$65.30M-0.41100Analyst ForecastShort Interest ↑News CoverageKPTIKaryopharm Therapeutics4.1093 of 5 stars$7.66+11.2%$57.50+650.7%-70.2%$64.50M$145.24M-7.51380Short Interest ↓High Trading VolumeBYSIBeyondSpringN/A$1.65-1.2%N/A-40.8%$64.40M$1.88M0.0080ENTXEntera Bio2.5135 of 5 stars$1.78-5.8%$10.00+461.8%+37.2%$63.70M$99,000.00-6.8520CTORCitius OncologyN/A$0.89-5.3%$3.00+237.1%N/A$63.68MN/A0.00N/AGap UpPYXSPyxis Oncology1.586 of 5 stars$1.07-7.8%$9.20+759.8%-78.3%$63.63M$16.15M-1.0460Upcoming EarningsGap DownQNCXQuince Therapeutics2.2171 of 5 stars$1.44-4.6%$9.50+559.7%+24.1%$63.36MN/A-1.1660PMVPPMV Pharmaceuticals2.4667 of 5 stars$1.22-0.8%$5.50+350.8%-28.4%$63.13MN/A-1.2250Positive NewsMRSNMersana Therapeutics4.0057 of 5 stars$0.50-7.9%$4.25+748.0%-90.8%$62.47M$40.50M-0.82150VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeVORVor Biopharma1.7514 of 5 stars$0.90-10.0%$11.36+1,161.8%-53.6%$61.81MN/A-0.55140 Remove Ads Related Companies and Tools Related Companies Karyopharm Therapeutics Alternatives BeyondSpring Alternatives Entera Bio Alternatives Citius Oncology Alternatives Pyxis Oncology Alternatives Quince Therapeutics Alternatives PMV Pharmaceuticals Alternatives Mersana Therapeutics Alternatives Viveon Health Acquisition Alternatives Vor Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MEIP) was last updated on 3/17/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
